CHIESI FARMACEUTICI S.P.A.
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
Clinical Trials
475
Trial Phases
5 Phases
Drug Approvals
88
Drug Approvals
Beclometasone Dipropionate and Formoterol Fumarate Powder for Inhalation
- Product Name
- 倍氯米松福莫特罗吸入粉雾剂
- Approval Number
- 国药准字HJ20240144
- Approval Date
- Dec 1, 2024
Beclometasone Dipropionate Suspension for Inhalation
- Product Name
- 吸入用丙酸倍氯米松混悬液
- Approval Number
- 国药准字HJ20130214
- Approval Date
- Feb 14, 2023
Beclometasone Dipropionate，Formoterol Fumarate and Glycopyrrolate Inhalation Aerosol
- Product Name
- 倍氯福格吸入气雾剂
- Approval Number
- 国药准字HJ20220035
- Approval Date
- Apr 12, 2022
Budesonide Pressurised Inhalation Solution
- Product Name
- 布地奈德吸入气雾剂
- Approval Number
- H20120320
- Approval Date
- Feb 13, 2020
Clinical Trials
Distribution across different clinical trial phases (363 trials with phase data)• Click on a phase to view related trials
Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and Removed in Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- Biological: CHF6467 Part 1 (SAD)Drug: PlaceboBiological: CHF6467 Part 2 (MAD)
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 68
- Registration Number
- NCT07163182
- Locations
- 🇧🇬
Bulgaria MC Comac Medical Ltd., Sofia, Bulgaria
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
- Conditions
- Fabry DiseasePregnancyPregnancy Complications
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 10
- Registration Number
- NCT06941025
- Locations
- 🇬🇧
No physical study sites - Decentralized, web-based registry, London, United Kingdom
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
- Conditions
- Epidermolysis BullosaJunctional Epidermolysis BullosaEpidermolysis Bullosa, DystrophicEpidermolysis Bullosa, JunctionalSkin AbnormalitiesCongenital AbnormalitiesConnective Tissue DiseaseCollagen DiseasesSkin DiseasesGenetic Diseases, Inborn
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 6
- Registration Number
- NCT06917690
- Locations
- 🇯🇵
Kurume University Hospital, Fukuoka, Japan
🇯🇵Niigata University Medical and Dental Hospital, Niigata, Japan
🇯🇵Hokkaido University Hospital, Sapporo-shi, Japan
A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 50
- Registration Number
- NCT06900816
- Locations
- 🇧🇬
Medical Centre Comac Medical Ltd., Sofia, Krasno Selo District, Bulgaria
Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 30
- Registration Number
- NCT06892756
- Locations
- 🇧🇬
Medical Centre Comac Medical Ltd, Sofia, Bulgaria
- Prev
- 1
- 2
- 3
- 4
- 5
- 35
- Next
News
FDA Accepts Chiesi's New Drug Application for Triple Combination Asthma Inhaler
The FDA has accepted Chiesi's New Drug Application for its investigational triple combination inhaler containing beclomethasone dipropionate, formoterol fumarate, and glycopyrrolate for maintenance treatment of asthma in adults.
Elgan Pharma and Chiesi Begin Phase 3 Trial of ELGN-2112 for Intestinal Malabsorption in Preterm Infants
Elgan Pharma and Chiesi Group have dosed the first patients in FIT-PIV, a Phase 3 trial evaluating ELGN-2112 for intestinal malabsorption in preterm infants.